Colorectal Cancer News in Brief: November 1

Briefly: Pancreatic cancer occurs in about on in five Lynch syndrome families, increasing risk for the cancer substantially. Colorectal cancer patients whose tumors don’t have EGFR on immunohistochemical testing can still benefit from Erbitux treatment. Patients learn more and like medical consultations better when doctors sit side-by-side with them to view tests. Gastroenterologists deployed in Iraq…  Read More

Early Tumor Shrinkage Points to Good Erbitux Outcomes

Patients with advanced colorectal cancer whose tumors have gotten smaller six weeks after starting treatment with Erbitux had a much longer time before their cancer got worse and almost twice the overall survival as patients whose tumors didn’t shrink. Patients in the BOND study had already gotten worse on standard chemotherapy and were receiving either Erbitux®…  Read More

FDA Approves Labeling Changes for Erbitux and Vectibix to Reflect KRAS Status

The Food and Drug Administration (FDA) has approved labeling changes for Vectibix and Erbitux to reflect studies that found the two drugs are not effective in patients whose tumors have mutated KRAS. The FDA has updated the indication and usage for Vectibix™  (panitumumab) and Erbitux® (cetuximab) to include a statement that: retrospective subset analyses of metastatic…  Read More

Adding Erbitux to First Line Chemotherapy with Avastin Hurts More than Helps

Adding Erbitux to standard first line treatment for colorectal cancer of CAPOX with Avastin doesn’t help.  In fact, patients who receive the additional agent have a shorter time until their cancer gets worse and have worse side effects. Results of a randomized phase III clinical trial that added the monoclonal antibody Erbitux® (cetuximab) to Xeloda® (capecitabine),…  Read More

Changes in Blood Magnesium Levels Predict Response to Erbitux

Hypomagnesemia, or reduced magnesium levels, is a side effect of Erbitux® (cetuximab) treatment.  Patients with colorectal cancer whose blood magnesium dropped the fastest also had the best response to Erbitux given with Camptosar® (irinotecan) . Italian researchers measured magnesium levels for 68 patients before treatment began and then 6 hours, 1 7, 14, 21, 50, and…  Read More